<DOC>
	<DOCNO>NCT00692614</DOCNO>
	<brief_summary>This study evaluate treatment effect three dose I-vation TA implant ( MK0140 ) diabetic patient clinically significant macular edema .</brief_summary>
	<brief_title>A Study MK0140 Diabetic Patients With Macular Edema ( 0140-001 )</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Patient clinically significant macular edema result diabetes ( Type I Type 2 ) Patient study eye , 20/40 20/160 vision Patient Type 1 Type 2 diabetes Patient agree remain abstinent use ( partner use ) 2 acceptable method birth control Patient active ocular infection either eye Patient intraocular pressure &gt; 22 mmHg diagnosis glaucoma Patient cystoid macular edema study eye Patient history elevate IOP response ocular steroid therapy either eye Patient intraocular surgery study eye within 6 month prior Visit 1 Patient HbAIc value &gt; 10 % Visit 1 Patient within last 4 month initiate intensive insulin treatment plan next 4 month Patient history cancer within 5 year prior sign inform consent Patient clinicallyrelevant chronic renal failure Patient high blood pressure Patient coronary heart disease Patient know allergy steroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>